'JAMA Neurology' publishes the results from Phase 1b/2a clinical trial of the neuroprotective drug ApTOLL for ischemic stroke

The results from APRIL study, previously presented at the International Stroke Conference 2023, indicate that ApTOLL showed good safety in 151 acute ischemic stroke patients.The article also highlights that the preliminary efficacy results show that ApTOLL significantly reduces mortality and long-term functional dis...

Related Keywords

Hebron ,Israel General ,Israel ,Madrid ,Spain ,Lhospitalet De Llobregat ,Comunidad Autonoma De Cataluna ,Lizasoain ,Navarra ,Casariego ,Asturias ,Arenillas ,Cantabria ,France ,Barcelona ,Spanish ,Cardona Portela ,Macarena Hern ,David Segarra ,Hebron University Hospital ,National Institutes Of Health ,Octubre University Hospital ,University Hospital In Sevilla Spain ,Princesa University Hospital ,European Union ,University Hospital Complex Spain ,International Stroke Conference ,Cajal University Hospital ,Toulouse University Hospital France ,Spanish Ministry Of Science ,Fe University Hospital ,Bellvitge University Hospital ,European Medicines Agency ,University Clinical Hospital Of Valladolid Spain ,Hospital University Of Lille France ,Hebron Research Institute ,Stroke Research Group ,National Institutes ,Stroke Scale ,Rankin Score ,Chief Medical Officer ,Chief Scientific Officer ,Ischemic Stroke Undergoing Endovascular ,Spanish Ministry ,Germans Trias ,Pujol University Hospital ,University Hospital Complex ,L Hospitalet De Llobregat ,Virgen Del Roc ,University Hospital ,Doctor Josep Trueta University Hospital ,University Clinical Hospital ,Toulouse University Hospital ,Hospital University ,Fondation Adolphe De Rothschild ,